Drugs / ATHENA-2 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06323525 | Apr 2024 → Apr 2026 overdue | non-Hodgkin lymphoma | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATHENA-2 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06323525 ↗ |
| Action | Inhibit | “selectively disabling the Power3 (SPPL3) gene” NCT06323525 ↗ |
| Modality | Cell therapy | “allogeneic CAR-T cell product” NCT06323525 ↗ |
| Target | CD19 | “a CD19-targeting, TRAC and Power3 (SPPL3) double genes deleted allogeneic CAR-T cell product” NCT06323525 ↗ |